CMG Pharmaceutical will manufacture pet treats and snacks and gradually include pet medications in its portfolio.
The Seoul-based company, part of the CHA Biomedical Group, confirmed to GlobalPETS that it is looking at a “variety of possibilities” with a focus on technology and investments in the pet industry.
AJU Daily reported earlier in the year that the medical company acquired ING Medix, a South Korean animal nutrition supplement maker. According to local media, the company would make use of its own distribution network to market and supply soft, chewy supplements.
In a statement to the press, CMG CEO Lee Ju-hyung said that it completed a hazard analysis procedure and is in the process of constructing smart factories.
He also stated that by 2030 the company aims to post annual sales of ₩50 billion ($38.5M/ €36M) in its pet business.
Pet ownership in the Asian country currently stands at 19.6%, according to a recent report by Statista
The latest articles
Almost 40% of vets are using AI tools to gain a competitive edge
A recent survey looks into awareness, perception, usage and concerns surrounding the adoption of AI in veterinary medicine.
Trends & Insights
18 Apr 2024
Analysis: Will Scotland implement a licensing scheme for pet services?
A government-led survey shows broad support for regulating dog walkers and dog groomers, among other pet services.
Global Pet Industry
18 Apr 2024
Danish BHJ acquires majority stake in Australian firm’s pet food manufacturer
The ingredient supplier is expected to help the firm expand its footprint into new markets.
Pet Food
17 Apr 2024
GET THE NEWSLETTER
Weekly newsletter to stay up-to-date
Discover what’s happening in the pet industry. Get the must-read stories and insights in your inbox.